These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 18082202)

  • 1. Computational repositioning and preclinical validation of pentamidine for renal cell cancer.
    Zerbini LF; Bhasin MK; de Vasconcellos JF; Paccez JD; Gu X; Kung AL; Libermann TA
    Mol Cancer Ther; 2014 Jul; 13(7):1929-1941. PubMed ID: 24785412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kidney cancer pathology in the new context of targeted therapy.
    Allory Y; Culine S; de la Taille A
    Pathobiology; 2011; 78(2):90-8. PubMed ID: 21677472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tumor profiling of renal cell tumors: relevance for diagnostics and therapy].
    Junker K; Steiner T; Sanjmyatav J; Pilchowski R; Heinze C; Walter M; Schubert J
    Pathologe; 2009 Mar; 30(2):105-10. PubMed ID: 19089427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomics and proteomics in renal cell carcinoma: diagnosis, prognosis, and treatment selection.
    Jones J; Pantuck AJ
    Curr Urol Rep; 2008 Jan; 9(1):9-14. PubMed ID: 18366968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
    McDermott DF; Regan MM; Atkins MB
    Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer.
    Jones J; Otu HH; Grall F; Spentzos D; Can H; Aivado M; Belldegrun AS; Pantuck AJ; Libermann TA
    J Urol; 2008 Feb; 179(2):730-6. PubMed ID: 18082202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.
    Sabatino M; Kim-Schulze S; Panelli MC; Stroncek D; Wang E; Taback B; Kim DW; Deraffele G; Pos Z; Marincola FM; Kaufman HL
    J Clin Oncol; 2009 Jun; 27(16):2645-52. PubMed ID: 19364969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dorsal Muscle Attenuation May Predict Failure to Respond to Interleukin-2 Therapy in Metastatic Renal Cell Carcinoma.
    Otemuyiwa B; Derstine BA; Zhang P; Wong SL; Sabel MS; Redman BG; Wang SC; Alva AS; Davenport MS
    Acad Radiol; 2017 Sep; 24(9):1094-1100. PubMed ID: 28341412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
    McDermott DF; Atkins MB
    Semin Oncol; 2006 Oct; 33(5):583-7. PubMed ID: 17045087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices.
    Poon TC
    Expert Rev Proteomics; 2007 Feb; 4(1):51-65. PubMed ID: 17288515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.
    Aivado M; Spentzos D; Germing U; Alterovitz G; Meng XY; Grall F; Giagounidis AA; Klement G; Steidl U; Otu HH; Czibere A; Prall WC; Iking-Konert C; Shayne M; Ramoni MF; Gattermann N; Haas R; Mitsiades CS; Fung ET; Libermann TA
    Proc Natl Acad Sci U S A; 2007 Jan; 104(4):1307-12. PubMed ID: 17220270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
    Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Rixe O; Oudard S; Negrier S; Szczylik C; Kim ST; Chen I; Bycott PW; Baum CM; Figlin RA
    N Engl J Med; 2007 Jan; 356(2):115-24. PubMed ID: 17215529
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.